If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Cibaria fere eadem sunt utrique generi praebenda. Nam si tam laxa rura sunt, ut sustineant pecorum greges, omnis sine discrimine hordeacea farina cum sero commode pascit. Sin autem surculo consitus ager sine pascuo est, farreo vel triticeo pane satiandi sunt, admixto tamen liquore coctae fabae, sed tepido, nam fervens rabiem creat. "Provisions of victuals are almost the same for both [types of dog]. If the fields are so large as to sustain herds of animals, barley meal mixed with whey is a convenient food. But if it is an orchard without grain, spelt or wheat bread is fed mixed with the liquid from cooked beans, but warm, for boiling creates rabies." In the Avesta, written from 224 to 651 CE, Ahura Mazda advises:
Global Positioning System (GPS) – The most widely used satellite navigation system, maintained by the US Air Force, which uses a constellation of 31 satellites in low Earth orbit. The orbits of the satellites are distributed so at any time at least four satellites are above the horizon over each point on Earth. Each satellite has an onboard atomic clock and transmits a continuous radio signal containing a precise time signal as well as its current position. Two frequencies are used, 1.2276 and 1.57542 GHz. Since the velocity of radio waves is virtually constant, the delay of the radio signal from a satellite is proportional to the distance of the receiver from the satellite. By receiving the signals from at least four satellites a GPS receiver can calculate its position on Earth by comparing the arrival time of the radio signals. Since each satellite's position is known precisely at any given time, from the delay the position of the receiver can be calculated by a microprocessor in the receiver. The position can be displayed as latitude and longitude, or as a marker on an electronic map. GPS receivers are incorporated in almost all cellphones and in vehicles such as automobiles, aircraft, and ships, and are used to guide drones, missiles, cruise missiles, and even artillery shells to their target, and handheld GPS receivers are produced for hikers and the military. Radio beacon – a fixed location terrestrial radio transmitter which transmits a continuous radio signal used by aircraft and ships for navigation.
proteome The entire set of proteins that is or can be expressed by a particular genome, cell, tissue, or species at a particular time (such as during a single lifespan or during a specific developmental stage) or under particular conditions (such as when compromised by a certain disease).
==== France ==== On 5 June 1916, Tolkien boarded a troop transport for an overnight voyage to Calais. Like other soldiers arriving for the first time, he was sent to the British Expeditionary Force's base depot at Étaples. On 7 June, he was informed that he had been assigned as a signals officer to the 11th (Service) Battalion, Lancashire Fusiliers. The battalion was part of the 74th Brigade, 25th Division. While waiting to be summoned to his unit, Tolkien sank into boredom. To pass the time, he composed a poem titled The Lonely Isle, which was inspired by his feelings during the sea crossing to Calais. To evade the British Army's postal censorship, he developed a code of dots by which Edith could track his movements. He left Étaples on 27 June 1916 and joined his battalion at Rubempré, near Amiens. He found himself commanding enlisted men who were drawn mainly from the mining, milling, and weaving towns of Lancashire. According to John Garth, he "felt an affinity for these working class men", but military protocol prohibited friendships with "other ranks". Instead, he was required to "take charge of them, discipline them, train them, and probably censor their letters ... If possible, he was supposed to inspire their love and loyalty." Tolkien later lamented, "The most improper job of any man ... is bossing other men. Not one in a million is fit for it, and least of all those who seek the opportunity."
Sources: en.wikipedia.org
Intracellular Hbs. These globins reside inside a cell, much like the vertebrate Hb. Multi-subunit Hbs. These globins form complexes and work outside a cell. Multi-domain, multisubunit Hbs. These globins form complexes, work outside a cell, and have multiple globin domains per peptide chain. Erythrocruorin and chlorocruorin belong to the multisubunit Hbs, specifically of the 12-dodecamer type.
=== Microstructures === The interplay of molecular scale mechanisms and hierarchical surface structures is known to result in high levels of static friction and bonding between pairs of surfaces. Technologically advanced adhesive devices sometimes make use of microstructures on surfaces, such as tightly packed periodic posts. These are biomimetic technologies inspired by the adhesive abilities of the feet of various arthropods and vertebrates (most notably, geckos). By intermixing periodic breaks into smooth, adhesive surfaces, the interface acquires valuable crack-arresting properties. Because crack initiation requires much greater stress than does crack propagation, surfaces like these are much harder to separate, as a new crack has to be restarted every time the next individual microstructure is reached.
=== Toxicity === Ingesting less than 1.5 g (1⁄16 oz) of saffron is not toxic for humans, but doses greater than 5 g (3⁄16 oz) can become increasingly toxic. Mild toxicity includes dizziness, nausea, vomiting, and diarrhea, whereas at higher doses there can be reduced platelet count and spontaneous bleeding.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.